Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 221

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 221
---
 Warrants”), at the reduced exercise price of $ 0.58 per share. The Company received aggregate gross proceeds of approximately $ 1.4 million, before deducting advisory fees and other expenses payable by it. In consideration of the immediate exercise of the October Warrants and August Warrants by the holders thereof in accordance with the February Inducement Agreement, the Company issued unregistered common warrants to purchase an aggregate of up to 2,926,166 shares of Common Stock ( 120% of the number of shares of Common Stock issuable upon exercise of the October Warrants and August Warrants) to such holders.

| F-29 |

<div align='center'>bioAffinity Technologies, Inc.

2,851,586 Shares of Common Stock

, 2025</div>

<div align='center'>PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 13. Other Expenses of Issuance and Distribution

The following table sets forth all expenses to be paid by the registrant, other than estimated underwriting discounts and commissions, in connection with this Offering. All of the amounts shown are estimates except for the SEC registration fee and the FINRA filing fee.

|                                                     |     | Amount         
 to be Paid (1) |         |
|:----------------------------------------------------|:----|:---------------|--------:|
| Securities and Exchange Commission registration fee |     | $              |     514 |
| Legal fees and expenses                             |     |                |  75,000 |
| Accounting fees and expenses                        |     |                |  15,000 |
| Miscellaneous                                       |     |                |   9,486 |
| Total                                               |     | $              | 100,000 |

(1) The amount of fees and expenses listed in
this Item 13 were in connection with the Registration Statement on Form S-1 (File No. 333-283521), initially filed by bioAffinity Technologies,
Inc. on November 27, 2024 and declared effective by the SEC on December 6, 2024.

Item 14. Indemnification of Directors and Officers

bioAffinity Technologies, Inc. is incorporated under the laws of the State of Delaware. Reference is made to Section 102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director’s fiduciary duty, except (1) for